Philippine Health Research Registry
Display Options
Results List
Results 1 - 6 of 6 Albert Albay, Jr. MD research(es)

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Completed
Project Description:
The purpose of this study is to prospectively evaluate the effect of the once daily ICS/LABA combination Fluticasone Furoate (FF)/Vilanterol (VI) inhalation powder on survival in subjects with moderate COPD (≥50 and ≤70 % predicted FEV1) and a history of or at increased risk for cardiovascular disease.
[2]
 
Project Status:
Ongoing
Project Description:
This study will recruit patients worldwide at approximately 330 sites in about 25 countries. The target is to randomise 4114 male and female patients. The sample size will be re-estimated based on blinded review during the study. The number of patients might be increased up to a maximum of 6171 patients.
Project Status:
Pending
Project Description:
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstruc... [read more]
Project Status:
Ongoing
Project Description:
Safety and Efficacy study of QVM149 in asthmatic patients
Project Status:
Ongoing
Project Description:
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the onset of effect and the safety of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) to patients with severe, uncontrolled asthma. Approximately 230 patients with peripheral blood eosinophil counts ≥300 cells/μL will be randomiz... [read more]
[6]
 
Project Status:
Pending
Project Description:
This is a Phase 3, multicenter (multinational), double-blind, parallel-group, randomized, active-controlled study in approximately 300 subjects with documented nosocomial1 pneumonia caused by Gram-negative bacteria. Subjects meeting eligibility criteria and assessed by the investigator to require 7 to 14 days of intravenous treatment in hospital wi... [read more]